Evidence map›Paper›PMID 37704825›Full record

ArticleVirchows Archiv : an international journal of pathology2024

Distinct patterns of biomarker expression for atypical intraductal proliferations in prostate cancer.

Carmela Martini, Jessica M Logan, Alexandra Sorvina, Sarita Prabhakaran, Benjamin S Y Ung, Ian R D Johnson, Shane M Hickey, Robert D Brooks, kConFab Consortium, Maria C Caruso and 6 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Carmela MartiniClinical and Health Sciences, University of South Australia, Adelaide, Australia. carmela.martino@unisa.edu.au.ORCID http://orcid.org/0000-0002-3891-7696
Jessica M LoganClinical and Health Sciences, University of South Australia, Adelaide, Australia.
Alexandra SorvinaClinical and Health Sciences, University of South Australia, Adelaide, Australia.
Sarita PrabhakaranDepartment of Anatomical Pathology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Benjamin S Y UngClinical and Health Sciences, University of South Australia, Adelaide, Australia.
Ian R D JohnsonClinical and Health Sciences, University of South Australia, Adelaide, Australia.
Shane M HickeyClinical and Health Sciences, University of South Australia, Adelaide, Australia.
Robert D BrooksClinical and Health Sciences, University of South Australia, Adelaide, Australia.
kConFab Consortium
Maria C CarusoClinical and Health Sciences, University of South Australia, Adelaide, Australia.
Sonja KlebeDepartment of Anatomical Pathology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Litsa KarageorgosClinical and Health Sciences, University of South Australia, Adelaide, Australia.
John J O'LearyDepartment of Histopathology, Trinity College Dublin, Dublin, Ireland.
Brett DelahuntMalaghan Institute for Medical Research, Wellington, New Zealand.
Hemamali SamaratungaAquesta Uropathology and the University of Queensland, Brisbane, Qld, Australia.
Douglas A BrooksClinical and Health Sciences, University of South Australia, Adelaide, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade prostatic intraepithelial neoplasia (HGPIN) is a well-characterised precursor lesion in prostate cancer. The term atypical intraductal proliferations (AIP) describes lesions with features that are far too atypical to be considered HGPIN, yet insufficient to be diagnosed as intraductal carcinoma of the prostate (IDCP). Here, a panel of biomarkers was assessed to provide insights into the biological relationship between IDCP, HGPIN, and AIP and their relevance to current clinicopathological recommendations. Tissue samples from 86 patients with prostate cancer were assessed by routine haematoxylin and eosin staining and immunohistochemistry (IHC) with a biomarker panel (Appl1/Sortilin/Syndecan-1) and a PIN4 cocktail (34βE12+P63/P504S). Appl1 strongly labelled atypical secretory cells, effectively visualising intraductal lesions. Sortilin labelling was moderate-to-strong in > 70% of cases, while Syndecan-1 was moderate-to-strong in micropapillary HGPIN/AIP lesions (83% cases) versus flat/tufting HGPIN (≤ 20% cases). Distinct biomarker labelling patterns for atypical intraductal lesions of the prostate were observed, including early atypical changes (flat/tufting HGPIN) and more advanced atypical changes (micropapillary HGPIN/AIP). Furthermore, the biomarker panel may be used as a tool to overcome the diagnostic uncertainty surrounding AIP by supporting a definitive diagnosis of IDCP for such lesions displaying the same biomarker pattern as cribriform IDCP.

Indexed as

Biomarkers, TumorProstatic Intraepithelial NeoplasiaProstatic NeoplasmsAgedAged, 80 and overCarcinoma, Intraductal, NoninfiltratingCell ProliferationHumansImmunohistochemistryMaleMiddle AgedBiomarkers, TumorAtypical intraductal proliferationBiomarkersDiagnosisHigh-grade prostatic intraepithelial neoplasiaImmunohistochemistryProstatic adenocarcinoma

Identifiers

PMID37704825
PMCPMC11522086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.